发明授权
US07632821B2 Ribonucleoside cyclic acetal derivatives for the treatment of RNA-dependent RNA viral infection
失效
用于治疗RNA依赖性RNA病毒感染的核糖核苷环缩醛衍生物
- 专利标题: Ribonucleoside cyclic acetal derivatives for the treatment of RNA-dependent RNA viral infection
- 专利标题(中): 用于治疗RNA依赖性RNA病毒感染的核糖核苷环缩醛衍生物
-
申请号: US11990051申请日: 2006-08-04
-
公开(公告)号: US07632821B2公开(公告)日: 2009-12-15
- 发明人: Gabor Butora , Kenneth Alan Koeplinger , Malcolm MacCoss , Daniel R. McMasters , David B. Olsen , Lihu Yang
- 申请人: Gabor Butora , Kenneth Alan Koeplinger , Malcolm MacCoss , Daniel R. McMasters , David B. Olsen , Lihu Yang
- 申请人地址: US NJ Rahway
- 专利权人: Merck & Co., Inc.
- 当前专利权人: Merck & Co., Inc.
- 当前专利权人地址: US NJ Rahway
- 代理商 Kenneth R. Walton; Sheldon O. Heber; Philippe L. Durette
- 国际申请: PCT/US2006/030549 WO 20060804
- 国际公布: WO2007/021610 WO 20070222
- 主分类号: A01N43/04
- IPC分类号: A01N43/04 ; A61K31/70
摘要:
The present invention provides ribonucleoside 2′,3′-cyclic acetals of structural formula I which are precursors or prodrugs of inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors of inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as precursors or prodrugs of inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors or prodrugs of inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such ribonucleoside 2′,3′-cyclic acetals alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the ribonucleoside 2′,3′-cyclic acetals of the present invention.
公开/授权文献
信息查询
IPC分类: